{"meshTags":["Antineoplastic Combined Chemotherapy Protocols","Aromatase Inhibitors","Breast Neoplasms","Female","Humans","Mastectomy","Neoplasm Staging","Prognosis","Radiotherapy","Sentinel Lymph Node Biopsy","Tamoxifen"],"meshMinor":["Antineoplastic Combined Chemotherapy Protocols","Aromatase Inhibitors","Breast Neoplasms","Female","Humans","Mastectomy","Neoplasm Staging","Prognosis","Radiotherapy","Sentinel Lymph Node Biopsy","Tamoxifen"],"organisms":["9606"],"publicationTypes":["Journal Article","Research Support, Non-U.S. Gov\u0027t","Research Support, U.S. Gov\u0027t, Non-P.H.S.","Review"],"abstract":"In the United States, more than 90% of breast cancer diagnoses occur in an early stage of the disease. That so much detection happens early bodes well for the patient. However, it is only one part of the clinical picture. Various features, such as lymph node involvement and receptor status, help predict outcome, aid in treatment selection, and are crucial factors in survival. Here, the authors present the current considerations and treatment guidelines for early-stage breast cancer.","title":"Managing early breast cancer: prognostic features guide choice of therapy.","pubmedId":"15510591"}